European Growth Stocks With High Insider Ownership To Watch

Simply Wall St.
27 Mar

As the European market navigates a complex landscape of trade tensions and economic uncertainties, the pan-European STOXX Europe 600 Index has managed to break a two-week losing streak, buoyed by hopes for increased government spending. In this environment, growth companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business.

Top 10 Growth Companies With High Insider Ownership In Europe

Name Insider Ownership Earnings Growth
Elicera Therapeutics (OM:ELIC) 27.8% 97.2%
Pharma Mar (BME:PHM) 11.8% 40.8%
Vow (OB:VOW) 13.1% 111.2%
Bergen Carbon Solutions (OB:BCS) 12% 50.8%
XTPL (WSE:XTP) 27.9% 118%
Elliptic Laboratories (OB:ELABS) 22.6% 88.2%
CD Projekt (WSE:CDR) 29.7% 40.9%
Ortoma (OM:ORT B) 27.7% 68.6%
Nordic Halibut (OB:NOHAL) 29.8% 56.3%
Circus (XTRA:CA1) 26% 51.4%

Click here to see the full list of 235 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

VusionGroup

Simply Wall St Growth Rating: ★★★★★☆

Overview: VusionGroup S.A. offers digitalization solutions for commerce across Europe, Asia, and North America, with a market cap of €3.28 billion.

Operations: The company generates revenue primarily through its segment focused on installing and maintaining electronic shelf labels, which accounted for €954.70 million.

Insider Ownership: 13.4%

Earnings Growth Forecast: 68.3% p.a.

VusionGroup's insider ownership aligns with its growth trajectory, as evidenced by a significant improvement in financials and strategic decisions. The company's revenue of €954.7 million in 2024 marks substantial growth from the previous year, reducing net losses to €28.9 million. Analysts anticipate VusionGroup's revenue to grow at 19.4% annually, outpacing the French market average, while profitability is expected within three years with high forecasted return on equity at 30.7%.

  • Delve into the full analysis future growth report here for a deeper understanding of VusionGroup.
  • Our valuation report unveils the possibility VusionGroup's shares may be trading at a premium.
ENXTPA:VU Ownership Breakdown as at Mar 2025

Etteplan Oyj

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Etteplan Oyj offers software and embedded solutions, industrial equipment and plant engineering, and technical communication services across Finland, Scandinavia, China, and Central Europe with a market cap of €300.47 million.

Operations: The company generates revenue from Engineering Solutions (€192.80 million), Software and Embedded Solutions (€97.36 million), and Technical Communication Solutions (€70.49 million) across its operational regions.

Insider Ownership: 14.1%

Earnings Growth Forecast: 23.5% p.a.

Etteplan Oyj's growth potential is underscored by its forecasted earnings increase of 23.5% annually, outpacing the Finnish market. Despite a high debt level and recent profit margin decline to 2.9%, the stock trades at a significant discount to its estimated fair value. Recent collaborations in renewable energy projects highlight strategic initiatives for sustainable growth. The company's revenue guidance for 2025 suggests moderate growth, with operating profit expected between €23 million and €30 million.

  • Take a closer look at Etteplan Oyj's potential here in our earnings growth report.
  • According our valuation report, there's an indication that Etteplan Oyj's share price might be on the expensive side.
HLSE:ETTE Earnings and Revenue Growth as at Mar 2025

Medicover

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Medicover AB (publ) offers healthcare and diagnostic services in Poland, Sweden, and internationally, with a market cap of SEK29.85 billion.

Operations: The company's revenue is derived from Diagnostic Services, which generated €658 million, and Healthcare Services, which contributed €1.46 billion.

Insider Ownership: 11.1%

Earnings Growth Forecast: 31.8% p.a.

Medicover's growth prospects are supported by substantial insider buying in recent months, with no significant sales. The company forecasts annual earnings growth of 31.8%, surpassing the Swedish market average. Despite slower revenue growth at 11.5% annually, it exceeds the national rate and is expected to reach over €2.2 billion in 2025. Recent leadership changes and a proposed dividend increase to €0.15 per share further highlight strategic positioning for future expansion amidst high-quality earnings challenges.

  • Get an in-depth perspective on Medicover's performance by reading our analyst estimates report here.
  • Our comprehensive valuation report raises the possibility that Medicover is priced higher than what may be justified by its financials.
OM:MCOV B Earnings and Revenue Growth as at Mar 2025

Turning Ideas Into Actions

  • Gain an insight into the universe of 235 Fast Growing European Companies With High Insider Ownership by clicking here.
  • Contemplating Other Strategies? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ENXTPA:VU HLSE:ETTE and OM:MCOV B.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10